Dhanuka Agritech has acquired international rights for two fungicides from Bayer AG for Rs 165 crore. The acquisition includes rights to Bayer's Melody brand, its sub-brands for Iprovalicarb, and ...

Dhanuka Agritech Ltd is foraying into the global markets by acquiring the international rights for marketing and distribution of two fungicides Iprovalicarb and Triadineol from Bayer AG in a ...

Dhanuka Agritech has acquired global rights for two Bayer fungicides, Melody and Triadinenol, for Rs 165 crore, expanding its reach in international markets. New Delhi, Jan 21 (PTI) Agrochemical maker ...

New Delhi, Jan 21 (PTI) Agrochemical maker Dhanuka Agritech on Monday said it has acquired international rights for two fungicides from Germany's Bayer AG for Rs 165 crore. The deal includes rights to ...

Acquisition of Iprovalicarb and Triadinenol grants Dhanuka access to markets in over 20 countries from LATAM, EMEA, ASIA, and ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Bayer BAYN-0.85%decrease; red down pointing triangle said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer, a win for ...

Bayer argues PCB levels were safe, blames school for ignoring warnings Previous trials resulted in over $1.5 billion in verdicts Jan 14 (Reuters) - A Washington jury on Tuesday ordered Bayer ...

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...

In the United States, Bayer will continue its multipronged strategy to significantly contain the Roundup™ litigation. Having achieved favorable outcomes in 15 of the last 22 trials, the company ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...